皮佩拉西林加剧了脏近端管道细胞中万科米辛诱导的毒性
Shingo Takada1, Yuya Takashima2, Riku Shinozaki2
1Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Hokkaido University of Science, 15-4-1 Maeda 7, Teine-ku, Sapporo 006-8585, Japan.
Biological & pharmaceutical bulletin
|April 13, 2025
概括
范科米辛 (VCM) 和皮佩拉西林/塔扎巴克坦 (PIPC/TAZ) 抗生素的组合可能会增加急性损伤 (AKI) 的风险. PIPC/TAZ直接损害细胞,恶化VCM诱导的毒性和NGAL生产,这表明增强AKI的机制.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 范科米辛 (VCM) 和皮佩拉西林/塔扎巴克坦 (PIPC/TAZ) 是严重感染的常见实证疗法.
- 在接受这种联合治疗的患者中,已观察到急性损伤 (AKI) 的发生率增加.
- 这种增加的AKI风险的潜在药理机制尚不清楚.
研究的目的:
- 研究VCM,PIPC和TAZ对细胞的直接细胞毒性.
- 阐明VCM和PIPC/TAZ组合加剧损伤的机制.
主要方法:
- 在体外研究使用HK-2细胞和人类脏靠近管状上皮细胞 (RPTEC).
- 评估了细胞活力,乳酸脱酶泄漏,和caspase-3/-7活动.
- 测量了与中性粒细胞凝酶相关的卡林 (NGAL) 产量.
主要成果:
- 在VCM,PIPC/TAZ和PIPC中表现出度依赖的细胞毒性.
- PIPC/TAZ或PIPC增强的VCM诱导的细胞活力降低和膜损伤增加 (LDH泄漏).
- VCM增加了酶活性,而PIPC/TAZ放大了VCM诱导的NGAL产生,表明了协同毒性.
结论:
- 皮佩拉西林/塔扎巴克坦对脏近道管状上皮细胞具有直接的细胞毒性.
- 这种直接毒性可能有助于在VCM和PIPC/TAZ联合治疗中观察到的AKI发病率增加.
- 结果可能会为预防接受这种抗生素组合的患者的AKI策略提供信息.
相关概念视频
Drug Elimination by Renal Route: Tubular Secretion
2.1K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.1K
Renal Drug Excretion: Tubular Secretion
91
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
91
Drug Elimination by Renal Route: Tubular Reabsorption
3.0K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.0K
Renal Drug Excretion: Tubular Reabsorption
61
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
61
Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa
112
The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
The pKa of a...
The pKa of a...
112
Renal Failure: Dose Adjustments
37
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
37


